Lactobacillus reuteri含有プロバイオティクスのHelicobacter pylori抑制効果に関する検討

この研究は, Lactobacillus reuteri strain SD 2112株 (L. reuteri) のH. pylori抑制効果の検討である.今回, 我々はL. reuteri含有整腸剤 [L. reuteri錠, Reuterina (ERINA CO., INC.)] の効果について検討を行った.[検討1]H. pylori菌量とUBT値の相関: H. pylori陽性消化性潰瘍患者の33名を, Group I (低菌量群), Group II (中菌量群), Group III (高菌量群) の3群に分類し, H. pylori培養と同時に尿素呼気試験 (UBT) を行っ...

Full description

Saved in:
Bibliographic Details
Published in感染症学雑誌 Vol. 81; no. 4; pp. 387 - 393
Main Authors 石田, 均, 菅野, 朝, 高橋, 信一, 田中, 昭文, 今瀬, 教人, 徳永, 健吾
Format Journal Article
LanguageJapanese
Published 一般社団法人 日本感染症学会 2007
Online AccessGet full text
ISSN0387-5911
1884-569X
DOI10.11150/kansenshogakuzasshi1970.81.387

Cover

Abstract この研究は, Lactobacillus reuteri strain SD 2112株 (L. reuteri) のH. pylori抑制効果の検討である.今回, 我々はL. reuteri含有整腸剤 [L. reuteri錠, Reuterina (ERINA CO., INC.)] の効果について検討を行った.[検討1]H. pylori菌量とUBT値の相関: H. pylori陽性消化性潰瘍患者の33名を, Group I (低菌量群), Group II (中菌量群), Group III (高菌量群) の3群に分類し, H. pylori培養と同時に尿素呼気試験 (UBT) を行った. [検討2]L. reuteriのH. pylori抑制効果: H. pylori陽性者35名と陰性者5名に, 二重盲検法による交差試験でL. reuteri錠またはplacebo錠を内服させた.UBTは基準値として測定した内服開始8週間前の値の他, 内服開始前, 開始後4週間および8週間に検査した.[成績1]H. pylori菌量とUBT値の間には, 正の相関が見られ, Group IとGroup IIIで有意差を認めた (p<0.05). [成績2]UBTは, L. reuteri錠の内服期間 (A群+B群) で, 前値100%から69.7±40% (p<0.05) と有意に減少した. 一方で, C群 (placebo内服群) ・D群 (H.pylori陰性L. reuteri錠内服群) では変動は認めなかった.[結論]L. reuteri含有整腸剤の内服により, UBT値は有意に減少した. また, L. reuteriはH. pylori菌量も減少させる可能性が示唆された.
AbstractList この研究は, Lactobacillus reuteri strain SD 2112株 (L. reuteri) のH. pylori抑制効果の検討である.今回, 我々はL. reuteri含有整腸剤 [L. reuteri錠, Reuterina (ERINA CO., INC.)] の効果について検討を行った.[検討1]H. pylori菌量とUBT値の相関: H. pylori陽性消化性潰瘍患者の33名を, Group I (低菌量群), Group II (中菌量群), Group III (高菌量群) の3群に分類し, H. pylori培養と同時に尿素呼気試験 (UBT) を行った. [検討2]L. reuteriのH. pylori抑制効果: H. pylori陽性者35名と陰性者5名に, 二重盲検法による交差試験でL. reuteri錠またはplacebo錠を内服させた.UBTは基準値として測定した内服開始8週間前の値の他, 内服開始前, 開始後4週間および8週間に検査した.[成績1]H. pylori菌量とUBT値の間には, 正の相関が見られ, Group IとGroup IIIで有意差を認めた (p<0.05). [成績2]UBTは, L. reuteri錠の内服期間 (A群+B群) で, 前値100%から69.7±40% (p<0.05) と有意に減少した. 一方で, C群 (placebo内服群) ・D群 (H.pylori陰性L. reuteri錠内服群) では変動は認めなかった.[結論]L. reuteri含有整腸剤の内服により, UBT値は有意に減少した. また, L. reuteriはH. pylori菌量も減少させる可能性が示唆された.
Author 石田, 均
田中, 昭文
徳永, 健吾
菅野, 朝
高橋, 信一
今瀬, 教人
Author_xml – sequence: 1
  fullname: 石田, 均
  organization: 杏林大学医学部第3内科
– sequence: 1
  fullname: 菅野, 朝
  organization: 杏林大学医学部第3内科
– sequence: 1
  fullname: 高橋, 信一
  organization: 杏林大学医学部第3内科
– sequence: 1
  fullname: 田中, 昭文
  organization: 杏林大学医学部第3内科
– sequence: 1
  fullname: 今瀬, 教人
  organization: 杏林大学医学部第3内科
– sequence: 1
  fullname: 徳永, 健吾
  organization: 杏林大学医学部第3内科
BookMark eNp1kL9Lw0AcxQ-pYK39H7o5peaaX3ejFLVCwUEFt_DN9dImjUnJtUPdmoBoBamLIhQH7SAWdRP69xwN-l9Yqbi5vAeP93nDW0e5MAo5QptYLWOMDXWrDaHgoWhFTWj3zkCIloeppZYJLmvEWkF5TIiuGCY9yaG8uogUg2K8hopCeI6qqlRXK0Ylj_w6sG7kAPOCoCdKMe91eezNR9NsfCnTO5m-ynQkk4lMXmR6LpMnmbzLZCYHbzUeeOyHXAClTj-IYi8b3swvPubDWfYwloPp1-2jHNzL5CqbjD-frzfQqguB4MVfL6Dj3Z2jak2pH-ztV7frio8pBcUFZjQYocQkDWoSnWiMWsTCwBziALe4Di51wDGYC4bm6gxzk3LTYRpozHBMrYAOl7u-6EKT253YO4W4b0Pc9VjA7X-uswm29aUs7vprsxbEtg_aN4pvjqw
ContentType Journal Article
Copyright 日本感染症学会
Copyright_xml – notice: 日本感染症学会
DOI 10.11150/kansenshogakuzasshi1970.81.387
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
EISSN 1884-569X
EndPage 393
ExternalDocumentID article_kansenshogakuzasshi1970_81_4_81_4_387_article_char_ja
GroupedDBID ALMA_UNASSIGNED_HOLDINGS
JSF
KQ8
OK1
RJT
SJN
ID FETCH-LOGICAL-j199a-fac5dc89868d968483c97871acb8bae7e4af9bab5cfa53f4c1e69e6bc3a3c5b63
ISSN 0387-5911
IngestDate Wed Sep 03 06:03:27 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 4
Language Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j199a-fac5dc89868d968483c97871acb8bae7e4af9bab5cfa53f4c1e69e6bc3a3c5b63
OpenAccessLink https://www.jstage.jst.go.jp/article/kansenshogakuzasshi1970/81/4/81_4_387/_article/-char/ja
PageCount 7
ParticipantIDs jstage_primary_article_kansenshogakuzasshi1970_81_4_81_4_387_article_char_ja
PublicationCentury 2000
PublicationDate 2007
PublicationDateYYYYMMDD 2007-01-01
PublicationDate_xml – year: 2007
  text: 2007
PublicationDecade 2000
PublicationTitle 感染症学雑誌
PublicationTitleAlternate 感染症誌
PublicationYear 2007
Publisher 一般社団法人 日本感染症学会
Publisher_xml – name: 一般社団法人 日本感染症学会
References 11) Kobayashi D, Eishi Y, Ohkusa T, Ishige I, Suzuki T, Minami J, et al. Gastric mucosal density of Helicobacter pylori estimated by real-time PCR compared with results of urea breath test and histological grading. J Med Microbiol 2002; 51 305-11.
26) Wu J, Wang XX, Takasaki M, Ohta A, Higuchi M, Ishimi Y: Cooperative effects of exercise training and genistein administration on bone mass in ovariectomized mice. J Bone Miner Res 2001; 16: 1829-36.
16) McGroarty JA: Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med icrobiol 1993; 6: 251-64.
19) Michetti P, Dorta G, Wiesel PH, Brassart D, Verdu E, Herranz M, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) Lal on Helicobacter pylori infection in humans. Digestion 1999; 60: 203-9.
2) Asaka M, Sugiyama T, Kato M, Satoh K, Kuwayama H, Fukuda Y, et al.: A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001; 6: 254-61.
5) Suzuki J, Mine T, Kobayasi I, Fujita T: Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. Helicobacter 1998; 3: 59-63.
18) Sakamoto I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y: Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother 2001; 47: 709-10.
13) Hazell SL, Lee A: Campylobacter pyloridis, urease, hydrogen ion back diffusion, and gastric ulcers. Lancet 1986; 5: 15-7.
25) Johnson C, Dicksved J, Jonsson H, Roos S: Anti Helicobacter pylori activity among lactic acid bacteria isolated from gastric biopsies and strains of Lactobacillus reuteri. Helicobacter 2003; 8: 473.
22) Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H: Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002; 32: 105-10.
14) Thomsen L, Tasman-Jones C, Morris A, Wiggins P, Lee S, Forlong C: Ammonia produced by Campylobacter pylori neutralizes H+ moving through gastric mucus. Scand J Gastroenterol 1989; 24: 761-8.
3) Miwa H, Nagahara A, Sato K, Ohkura R, Murai T, Shimizu H, et al.: Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. J Gastroenterol Hepatol 1999; 14: 317-21.
12) Chen X, Haruma K, Kamada T, Mihara M, Komoto K, Yoshihara M, et al. Factors that affect results of the 13C urea breath test in Japanese patients. Helicobacter 2000; 5: 98-103.
6) Uemura N, Okamoto S, Yamamoto S: Helocobacter pylori. Infection and the development of gastric cancer. N Engl J Med 2001; 345: 829-32.
7) Ohara S, Kato M, Asaka M, Toyota T: Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol 1998; 33: 6-13.
1) Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S, et al.: Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741-6.
8) Logan RP, Polson RJ, Misiewicz JJ, Rao G, Karim NQ, Newell D, et al. Simplified single sample 13Carbon urea breath test for Helicobacter pylori: comparison with histology, culture, and ELISA serology. Gut 1991; 32: 1461-4.
15) Chang YW, Min SK, Kim KJ, Han YS, Lee JH, Dong SH, et al. Delta (13) C-urea breath test value is a useful indicator for Helicobacter pylori eradication in patients with functional dyspepsia. J Gastroenterol Hepatol 2003; 18: 726-31.
24) Talarico TL, Dobrogosz WJ: Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri. Antimicrob Agents Chemother 1989; 33: 674-9.
4) Miwa H, Ohkura R, Murai T, Nagahara A, Yamada T, Ogihara T, et al.: Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population. Helicobacter 1998; 3132-8.
21) Valeur N, Engel P, Carbaj al N, Connolly E, Ladefoged K: Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract Appl Environ Microbiol 2004; 70: 1176-81.
17) Reid G, Bruce AW, McGroarty JA, Cheng KJ, Costerton JW: Is there a role for lactobacilli in prevention of urogenital and intestinal infections? Clin Microbiol Rev 1990; 3: 335-44.
23) Talarico TL, Casas IA, Chung TC, Dobrogosz WJ: Production and isolation of reuterin, a growth inhibitor produced by Lactobacillus reuteri. Antimicrob Agents Chemother 1988; 32: 1854-8.
10) Takahashi S, Igarashi H, Ishiyama N, Nakano M, Ozaki M, Ito M, et al. Serial change of gastric mucosa after challenging with Helicobacter pylori in the cynomolgus monkey. Zentralbl Bakteriol 1993; 280: 51-7.
20) Felley CP, Corthesy-Theulaz I, Rivero JL, Sipponen P, Kaufmann M, Bauerfeind P, et al. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001; 13: 25-9.
9) Graham DY, Klein PD, Evans DJ Jr, Evans DG, Alpert LC, Opekun AR, et al. Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet 1987; 23: 1174-7.
References_xml – reference: 15) Chang YW, Min SK, Kim KJ, Han YS, Lee JH, Dong SH, et al. Delta (13) C-urea breath test value is a useful indicator for Helicobacter pylori eradication in patients with functional dyspepsia. J Gastroenterol Hepatol 2003; 18: 726-31.
– reference: 19) Michetti P, Dorta G, Wiesel PH, Brassart D, Verdu E, Herranz M, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) Lal on Helicobacter pylori infection in humans. Digestion 1999; 60: 203-9.
– reference: 12) Chen X, Haruma K, Kamada T, Mihara M, Komoto K, Yoshihara M, et al. Factors that affect results of the 13C urea breath test in Japanese patients. Helicobacter 2000; 5: 98-103.
– reference: 4) Miwa H, Ohkura R, Murai T, Nagahara A, Yamada T, Ogihara T, et al.: Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population. Helicobacter 1998; 3132-8.
– reference: 10) Takahashi S, Igarashi H, Ishiyama N, Nakano M, Ozaki M, Ito M, et al. Serial change of gastric mucosa after challenging with Helicobacter pylori in the cynomolgus monkey. Zentralbl Bakteriol 1993; 280: 51-7.
– reference: 8) Logan RP, Polson RJ, Misiewicz JJ, Rao G, Karim NQ, Newell D, et al. Simplified single sample 13Carbon urea breath test for Helicobacter pylori: comparison with histology, culture, and ELISA serology. Gut 1991; 32: 1461-4.
– reference: 26) Wu J, Wang XX, Takasaki M, Ohta A, Higuchi M, Ishimi Y: Cooperative effects of exercise training and genistein administration on bone mass in ovariectomized mice. J Bone Miner Res 2001; 16: 1829-36.
– reference: 20) Felley CP, Corthesy-Theulaz I, Rivero JL, Sipponen P, Kaufmann M, Bauerfeind P, et al. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001; 13: 25-9.
– reference: 11) Kobayashi D, Eishi Y, Ohkusa T, Ishige I, Suzuki T, Minami J, et al. Gastric mucosal density of Helicobacter pylori estimated by real-time PCR compared with results of urea breath test and histological grading. J Med Microbiol 2002; 51 305-11.
– reference: 3) Miwa H, Nagahara A, Sato K, Ohkura R, Murai T, Shimizu H, et al.: Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. J Gastroenterol Hepatol 1999; 14: 317-21.
– reference: 5) Suzuki J, Mine T, Kobayasi I, Fujita T: Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. Helicobacter 1998; 3: 59-63.
– reference: 7) Ohara S, Kato M, Asaka M, Toyota T: Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol 1998; 33: 6-13.
– reference: 23) Talarico TL, Casas IA, Chung TC, Dobrogosz WJ: Production and isolation of reuterin, a growth inhibitor produced by Lactobacillus reuteri. Antimicrob Agents Chemother 1988; 32: 1854-8.
– reference: 13) Hazell SL, Lee A: Campylobacter pyloridis, urease, hydrogen ion back diffusion, and gastric ulcers. Lancet 1986; 5: 15-7.
– reference: 16) McGroarty JA: Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med icrobiol 1993; 6: 251-64.
– reference: 14) Thomsen L, Tasman-Jones C, Morris A, Wiggins P, Lee S, Forlong C: Ammonia produced by Campylobacter pylori neutralizes H+ moving through gastric mucus. Scand J Gastroenterol 1989; 24: 761-8.
– reference: 1) Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S, et al.: Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741-6.
– reference: 2) Asaka M, Sugiyama T, Kato M, Satoh K, Kuwayama H, Fukuda Y, et al.: A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001; 6: 254-61.
– reference: 21) Valeur N, Engel P, Carbaj al N, Connolly E, Ladefoged K: Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract Appl Environ Microbiol 2004; 70: 1176-81.
– reference: 17) Reid G, Bruce AW, McGroarty JA, Cheng KJ, Costerton JW: Is there a role for lactobacilli in prevention of urogenital and intestinal infections? Clin Microbiol Rev 1990; 3: 335-44.
– reference: 9) Graham DY, Klein PD, Evans DJ Jr, Evans DG, Alpert LC, Opekun AR, et al. Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet 1987; 23: 1174-7.
– reference: 24) Talarico TL, Dobrogosz WJ: Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri. Antimicrob Agents Chemother 1989; 33: 674-9.
– reference: 25) Johnson C, Dicksved J, Jonsson H, Roos S: Anti Helicobacter pylori activity among lactic acid bacteria isolated from gastric biopsies and strains of Lactobacillus reuteri. Helicobacter 2003; 8: 473.
– reference: 22) Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H: Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002; 32: 105-10.
– reference: 18) Sakamoto I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y: Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother 2001; 47: 709-10.
– reference: 6) Uemura N, Okamoto S, Yamamoto S: Helocobacter pylori. Infection and the development of gastric cancer. N Engl J Med 2001; 345: 829-32.
SSID ssib000940252
ssib008799519
ssib058493432
ssib000959785
ssib020873179
ssib028667260
ssib002821772
ssj0000816464
ssib003038878
ssib002670505
ssib050995440
Score 1.7517363
Snippet この研究は, Lactobacillus reuteri strain SD 2112株 (L. reuteri) のH. pylori抑制効果の検討である.今回, 我々はL. reuteri含有整腸剤 [L. reuteri錠, Reuterina (ERINA...
SourceID jstage
SourceType Publisher
StartPage 387
Title Lactobacillus reuteri含有プロバイオティクスのHelicobacter pylori抑制効果に関する検討
URI https://www.jstage.jst.go.jp/article/kansenshogakuzasshi1970/81/4/81_4_387/_article/-char/ja
Volume 81
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 感染症学雑誌, 2007/07/20, Vol.81(4), pp.387-393
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1884-569X
  dateEnd: 20141231
  omitProxy: true
  ssIdentifier: ssj0000816464
  issn: 0387-5911
  databaseCode: KQ8
  dateStart: 19700101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1da9RAMJQK4osoKn5zgosPcvXysZvZx6TNUaQKQgt9O5K9RO9a2qK9l771DkQrSH1RhOKD9kEs6pvQ3xN66L9wZje5S6FK_XgJk83O7OxMsjM72Z21rJs8dRMnbWR10Xb9updKp54kXNYzFWdtpVKHKwoN3LsvZhe8u4t8cWLyRmXVUm89mVIbR-4r-RutYhnqlXbJ_oFmR0SxAGHUL15Rw3g9lo7n6LCcJFad5eUehf_peIYOiziTDRaELBJMTjOQLHIZuEz6BRDMlCUNDTgs8EogKB6BKEvcEmgWQGgI2iyI0Gjhm5TojM-312ju36FWIWDSJj4AWCg0EGg0ZCgingp8ZFEyKVjgFCVSFm2A5h7ZosrAAmAQVf1o3Qo-bWqaTSaRS596CD41hz0MhCYeak6AOgajgLCu22ShQfJY2KA3TQtuho0tM-FBkwEnSkgYIlNNi1XOjKtJ6ooEzbIk3nU1pNtkga0BJNQ41Lpu1DxBZkuy-oYAUbJRBmT80cczoqfZQ4xpIoiiCiPdg1CrTFDvJNeVUfaBoY_1eME_oR1HhoiPnQ0qBoPyJHNZGK_UGDQAr86FPq54ZPHMITnFl-1VzJdb9M14Qq45u_III8tpWepSTH8_njxafRgv9TZwqveoY0u_MQX21IjOoUzmxXfS-gViC-yWZy6I3ypr0-7DVhenQCccCrnRuosHlRmE9NBrr3joEmfIlXRMjvDprMZqhMH2_WrGPBfN7JgeUILEcYZDBwtce_wj2wEhfGccUUB3W3JvnC4J3Xk52qqtnUGgBH4miV2hnZPWrVKKd34vQ_SKuzhHLNeXapd3_ox1upir1gIjorPWRDc-Z3UPDTq1YtA52N4b7jzPB2_ywed8sJ33d_P-p3zwNO9_yPtf8_5-vvmlOljUzGAx3Hp18Ozbwdb-8N1Ovrn34_X7fPNt3n8x3N35_vHleWuhGc1Pz9aLA1vqXVvKuJ7FircVSBDQlgI8cBUqw7djlUASp37qxZlM4oSrLOZu5ik7FTIViXJjV_FEuBesyZXVlfSiVWtkMZ1cYSeZUhSDSXxoA0hbpRIxwL5kzRnRtNZMVp7WP71dl_8vuSvWKfMPiEK1V63J9ce99BpOXtaT6_r1_QmqKxTB
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lactobacillus+reuteri%E5%90%AB%E6%9C%89%E3%83%97%E3%83%AD%E3%83%90%E3%82%A4%E3%82%AA%E3%83%86%E3%82%A3%E3%82%AF%E3%82%B9%E3%81%AEHelicobacter+pylori%E6%8A%91%E5%88%B6%E5%8A%B9%E6%9E%9C%E3%81%AB%E9%96%A2%E3%81%99%E3%82%8B%E6%A4%9C%E8%A8%8E&rft.jtitle=%E6%84%9F%E6%9F%93%E7%97%87%E5%AD%A6%E9%9B%91%E8%AA%8C&rft.au=%E7%9F%B3%E7%94%B0%2C+%E5%9D%87&rft.au=%E8%8F%85%E9%87%8E%2C+%E6%9C%9D&rft.au=%E9%AB%98%E6%A9%8B%2C+%E4%BF%A1%E4%B8%80&rft.au=%E7%94%B0%E4%B8%AD%2C+%E6%98%AD%E6%96%87&rft.date=2007&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E6%84%9F%E6%9F%93%E7%97%87%E5%AD%A6%E4%BC%9A&rft.issn=0387-5911&rft.eissn=1884-569X&rft.volume=81&rft.issue=4&rft.spage=387&rft.epage=393&rft_id=info:doi/10.11150%2Fkansenshogakuzasshi1970.81.387&rft.externalDocID=article_kansenshogakuzasshi1970_81_4_81_4_387_article_char_ja
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0387-5911&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0387-5911&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0387-5911&client=summon